Banner - NPPA Connect

NP/PA Connect
News
Media
Conferences
Events
Publication
CME/CE
Resources
Editorial Advisory Board
Partners
Subscribe

Opinion|Videos|December 23, 2024

Spesolimab Safety Data

Key Takeaways

Panelists discuss how the safety data from the Effisayil 2 trial show that spesolimab was generally well-tolerated, with most adverse events being mild-to-moderate, primarily consisting of injection site reactions, and no new safety concerns emerging during the study.

Episodes in this series

EP. 1 Revolutionizing GPP Management: The Efficacy and Safety of Spesolimab in Preventing Life-Threatening Flares

EP. 1 Revolutionizing GPP Management: The Efficacy and Safety of Spesolimab in Preventing Life-Threatening Flares

EP. 2 Study Objectives and Key Inclusion Criteria for GPP Patients

EP. 2 Study Objectives and Key Inclusion Criteria for GPP Patients

EP. 3 Spesolimab Dosing Regimens

EP. 3 Spesolimab Dosing Regimens

EP. 4 Primary and Secondary Endpoints

EP. 4 Primary and Secondary Endpoints

EP. 5 Demographics and Baseline Characteristics Across Spesolimab Dose Groups

EP. 5 Demographics and Baseline Characteristics Across Spesolimab Dose Groups

EP. 6 Spesolimab Efficacy Data

EP. 6 Spesolimab Efficacy Data

EP. 7 Fighting the Flare of GPP: Expert Insights on Spesolimab

EP. 7 Fighting the Flare of GPP: Expert Insights on Spesolimab

EP. 8 Spesolimab Safety Data

EP. 8 Spesolimab Safety Data

EP. 9 Final Thoughts: The Spesolimab and GPP Flare Reduction

EP. 9 Final Thoughts: The Spesolimab and GPP Flare Reduction

Newsletter

Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.

Related Content

1 expert is featured in this series

The Ongoing Role of Topical Therapy in Plaque Psoriasis Management

ByTina Bhutani-Jacques, MD

July 21st 2026

Systemic JAK Inhibitors for Vitiligo: Emerging Clinical Trial Data and Safety Considerations

ByNada Elbuluk, MD, MSc, FAAD,Susan Taylor, MD, FAAD

July 21st 2026

JAK Inhibitors in Vitiligo: Mechanism, Efficacy, and Durability

ByNada Elbuluk, MD, MSc, FAAD,Susan Taylor, MD, FAAD

July 21st 2026

2 experts are featured in this series

The Safety of Advanced Topical Therapies in Inflammatory Dermatoses

ByPeter Lio, MD,Alexandra K. Golant, MD

July 15th 2026

2 experts are featured in this series

Understanding Corticosteroid-Related Medical-Legal Risks in Inflammatory Dermatoses

ByPeter Lio, MD,Alexandra K. Golant, MD

July 15th 2026

Latest CME

Assessing the Evidence for OX40-OX40L Axis Inhibition for the Treatment of Atopic Dermatitis

Assessing the Evidence for OX40-OX40L Axis Inhibition for the Treatment of Atopic Dermatitis

Johann Gudjonsson, MD, PhD; Christopher Bunick, MD, PhD

Navigating Safety Data with Janus Kinase (JAK) Inhibitors in Atopic Dermatitis (AD) Management

Navigating Safety Data with Janus Kinase (JAK) Inhibitors in Atopic Dermatitis (AD) Management

Andrew Alexis, MD, MPH; Leon Kircik, MD

Patient, Provider, and Caregiver Connection™: Addressing Patient Challenges With Holistic Approaches to Vitiligo Management

Patient, Provider, and Caregiver Connection™: Addressing Patient Challenges With Holistic Approaches to Vitiligo Management

Andrew F. Alexis, MD, MPH; Chesahna Kindred, MD, MBA, FAAD

Burst CME™: Optimizing Care for Patients with Psoriasis – Incorporating a Buy-and-Bill Model for Biologic Agents into Dermatological Practice

Burst CME™: Optimizing Care for Patients with Psoriasis – Incorporating a Buy-and-Bill Model for Biologic Agents into Dermatological Practice

Jerry Bagel, MD, MS

Cases and Conversations™: Biologic Matchmaking in Psoriasis – Finding the Right Therapy for the Right Patient

Cases and Conversations™: Biologic Matchmaking in Psoriasis – Finding the Right Therapy for the Right Patient

Douglas DiRuggiero, DMSc, MHS, PA-C; Lakshi Aldredge, MSN, ANP-BC, DCNP, FAANP

Hidradenitis Suppurativa: Diving Deeper Into Disease Pathogenesis, Severity Assessment, and Holistic Management Approaches

Hidradenitis Suppurativa: Diving Deeper Into Disease Pathogenesis, Severity Assessment, and Holistic Management Approaches

Hadar Lev-Tov, MD; Martina Porter, MD

Clear Skin, Clear Mind: Integrating Mental Health into Psoriasis Care

Clear Skin, Clear Mind: Integrating Mental Health into Psoriasis Care

John Koo, MD; T.J. Chao, MPAS, PA-C

Trending on Dermatology Times

New Consensus Defines Remission, Disease Activity in Atopic Dermatitis

Real-World Study Finds Experienced Dermatologists Outperform AI in Skin Cancer Diagnosis

Zasocitinib Shows High Skin Clearance at Hard-to-Treat Psoriasis Sites

Beyond Retinol: Evaluating the Stability, Safety, and Gene-Expression Profile of Bakuchiol Ferulate

Switching from Biologics to Upadacitinib Yields Progressive Improvements in Moderate to Severe AD